This week's sponsor is Premier Research. | | Beating the Odds in Early-Phase Oncology Trials Despite advances in molecular targeting, developing new cancer drugs remains a long shot. Read our white paper for insights on maximizing early-phase trial success. Premier Research. It's what we do. Best. | Today's Rundown Sanofi culls ImmunoGen cancer drug from clinical pipeline Janssen, Theravance ink GI pact worth up to $1B De Rothschild raises €345M Europe-skewed life science fund [Sponsored] Can emerging technology help biopharma improve the returns on R&D? Celltex pairs with Texas A&M on exosome therapy for Alzheimer’s FDA clears seizure-detecting wearable for epilepsy patients Abcam, Molecular Devices join forces to develop immunoassays for researchers GSK's China bribery scandal lingers as U.K. continues its probe Featured Story | Wednesday, February 7, 2018 Sanofi has dropped an anticancer antibody-drug conjugate it licensed from ImmunoGen. The French pharma gained full control of the anti-LAMP1 drug as part of a recent deal but has now removed the asset from its pipeline. |
|
| This week's sponsor is Dell EMC. | | [Webinar] Is Your Life Science Data "F-A-I-R"? Tuesday, February 13 | 2pm ET / 11am PT Is Your Life Science Data "F-A-I-R"? Join DataFrameworks & Dell EMC in this webinar to discover a new approach to create scientific data that is findable, accessible, interoperable, and reusable. Register now! | Top Stories Wednesday, February 7, 2018 Theravance picked up $100 million up front to bring its JAK inhibitor through phase 2/3 trials in Crohn's disease and ulcerative colitis. The biotech could potentially earn another $900 million in milestones and royalties. Wednesday, February 7, 2018 Edmond De Rothschild Investment Partners has raised €345 million ($430 million) for its latest fund. The haul makes BioDiscovery 5 the largest fund dedicated to biotechs and medical devices in Europe and tees up Edmond De Rothschild to invest in 15 to 17 companies. Monday, February 5, 2018 While biopharma companies are investing more than ever to develop innovative therapies, returns are not keeping pace. How can emerging technologies help improve productivity? Learn more from Deloitte’s annual ROI analysis. Wednesday, February 7, 2018 Celltex Therapeutics has joined forces with Texas A&M Institute for Regenerative Medicine on a project that hopes to have a stem cell-derived therapy for Alzheimer’s in the clinic within three years. Wednesday, February 7, 2018 The FDA has approved Empatica’s seizure-detecting wearable for use by epilepsy patients. Empatica picked up the 510(k) clearance for Embrace after the device detected every seizure in a 135-patient clinical trial. Wednesday, February 7, 2018 Abcam, a supplier of protein research material and kits, has teamed up with bioanalytical measurement solutions expert Molecular Devices to develop screening tools for the life science industry. Wednesday, February 7, 2018 GlaxoSmithKline’s China bribery imbroglio is the scandal that just won’t die. After having paid more than half a billion dollars to lay to rest investigations by Chinese and U.S. authorities, the U.K. drugmaker has now been asked for new info from fraud investigators in its home country. This week's sponsor is IQVIA. | | Discover a new path to your success via Human Data Science. IMS Health and Quintiles are now IQVIA™ – created to advance your pursuits of human science by unleashing the power of data science and human ingenuity. Join the journey today. Learn More. | Resources Sponsored by: RBC Wealth Management Guiding corporate executives through regulatory complexities, while delivering an array of sophisticated investment options. Learn more. Presented by: Patheon Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties. Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? Watch this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue. Sponsored by: Veeva Systems Expanding into new markets places a spotlight on inefficient processes. Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA Healthcare Internet of Things February 13-14, 2018 | Moscone South Convention Center | San Francisco, CA PEGS: The Essential Protein Engineering Summit April 30-May 4 | Boston, MA |